Skip to main content
Premium Trial:

Request an Annual Quote

AssureRx Updates GeneSightRx Panel with New Gene: CYP1A2


Originally published March 8.

AssureRx has added a fifth gene, CYP1A2, to its laboratory-developed pharmacogenomic test GeneSightRx, the company announced this week.

GeneSightRx, which also analyzes CYP2D6, CYP2C19, the serotonin transporter gene SLC6A4, and the serotonin 2A receptor gene 5HTR2A, operates on the Luminex 200 platform using the xTag process. When AssureRx first launched the test in late 2009, the company described it as a "multivariate, algorithmic, interpretive" test that will guide psychiatric treatment decisions [see PGx Reporter 10-27-2009].

According to the company, GeneSightRx analyzes more than forty gene variants that affect patients' response to certain psychiatric drugs, including antidepressants and antipsychotics.

"GeneSightRx integrates the analysis of genes and their many variations to obtain an evidence-based pharmacogenetic profile," the company notes. "The gene variations are further analyzed against 26 FDA-approved drugs to help physicians select patient-appropriate psychotropic medications."

According to PharmGKB, the online pharmacogenomics information database, CYP2A2 variations have been associated in studies with response to the antianxiety drug alpraxolam, the antidepressant citalopram, and the schizophrenia drug clozapin, among others.

The Mayo Clinic and the Cincinnati Children's Hospital Medical Center were early-access users of GeneSightRx before its commercial launch.